Hellenic Institute For The Study Of Sepsis
Clinical trials sponsored by Hellenic Institute For The Study Of Sepsis, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to tame overactive immune response in sepsis Results expected Nov 2026 (estimated)
-
New drug aims to tame overactive immune response in sepsis
Disease control OngoingThis phase 2 trial tests emapalumab, a drug that blocks a protein called interferon-gamma, in 75 adults with sepsis caused by a specific immune overreaction. The goal is to see if the drug can reduce organ failure, measured by a drop in the SOFA score. Participants are in ICUs ac…
Phase 2 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New test combo could slash unnecessary antibiotic use in sepsis
Knowledge-focused OngoingThis study tests whether using rapid, advanced lab tests to identify the exact bacteria causing a severe infection can help doctors choose the right antibiotics faster. About 190 adults with sepsis in Greek ICUs will either get standard care or the new testing strategy. The goal …
Phase 3 • Sponsor: Hellenic Institute for the Study of Sepsis • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC